Nasdaq Stockholm

ODI Pharma AB (publ)

ISIN SE0013409760Filings at the FI

At a glance

Most recent filing on January 15, 2026 — an open-market purchase by Johan Edewaard on Jan 8, 2026.

We hold 6 visible filings, going back to January 23, 2020.

Filings we could not classify with confidence are set aside for review, so they are in none of these counts.

Insider trades

What is a MAR filing?

5 of 6 shown

This page is free to read, and it stops after 5 rows. Those are the 5 most recent filings at this company, out of 6. Reading the whole list, and the full version of the page each row opens (that page itself opens free, with its first rows), is part of the subscription. So are the price history with every buy marked, the price change beside each line, and any moments with several buyers or buying streaks. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Johan Edewaard Chief executive officer, Board member
37,600 SEKOpen-market buy
TradedJan 8, 2026FiledJan 15, 2026
Johan Edewaard Chief executive officer, Board member
10,413 SEKOpen-market buy
TradedJan 5, 2026FiledJan 15, 2026
Volker Wiederrich Chair of the board
700,000 SEKOther
TradedDec 6, 2023FiledDec 10, 2023
Derek Simmross Chief executive officer
8,050,000 SEKOther
TradedDec 6, 2023FiledDec 10, 2023
Derek Simmross Chief executive officer, Board member or deputy board member
1,543,222 SEKOpen-market sale
TradedJan 23, 2020FiledJan 24, 2020